BRISTOL MYERS SQUIBB CO

BMY 10-K · Q4 2025
API behind this page

BMY Q4 2025 request

Playground key active
Request URL /api/financials?ticker=BMY&year=2025&quarter=4
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q4 2025 Q4 2024 YoY
Revenue 12,502 12,342 +1.3%
Show Product Lines breakouts
Abecma 101 105 -3.8%
Abraxane 84 174 -51.7%
Alliance revenues 115 124 -7.3%
Alliance revenues · Collaborative Arrangement 115 124 -7.3%
Breyanzi 392 263 +49.0%
Camzyos 354 223 +58.7%
Eliquis 3,452 3,195 +8.0%
Gross product sales 23,537 22,373 +5.2%
Growth Portfolio 7,393 6,363 +16.2%
Krazati 56 39 +43.6%
Legacy Portfolio 5,109 5,979 -14.6%
Net product sales 12,111 11,811 +2.5%
Net product sales · Collaborative Arrangement 3,478 3,264 +6.6%
Opdivo 2,693 2,479 +8.6%
Opdualag 350 254 +37.8%
Orencia 1,008 1,000 +0.8%
Other Growth products 536 527 +1.7%
Other Legacy products 199 250 -20.4%
Pomalyst/Imnovid 692 823 -15.9%
Reblozyl 666 547 +21.8%
Revlimid 602 1,339 -55.0%
Sotyktu 85 83 +2.4%
Sprycel 80 198 -59.6%
Yervoy 810 675 +20.0%
Zeposia 159 158 +0.6%
Show Geography breakouts
Non Us 3,635 3,396 +7.0%
Other 309 350 -11.7%
US 8,558 8,596 -0.4%
Show — breakouts
Revenue 391 531 -26.4%
Revenue -892 -981 +9.1%
Revenue 277 407 -31.9%
Show Type Of Arrangement breakouts
Collaborative Arrangement 3,593 3,388 +6.1%
Cost of Revenue 4,097 4,812 -14.9%
Show Type Of Arrangement breakouts
Collaborative Arrangement 1,715 1,584 +8.3%
Selling, General & Administrative 2,181 2,136 +2.1%
Show Type Of Arrangement breakouts
Collaborative Arrangement 72 75 -4.0%
Research & Development 2,586 3,191 -19.0%
Show Nature Of Expense breakouts
Drug Development 1,223 1,222 +0.1%
Other 940 1,490 -36.9%
Other Research 423 479 -11.7%
Acquired I P R D 1,393 30 +4543.3%
Amortizationof Acquired Intangible Assets 826 1,693 -51.2%
Other Non-Operating Income (Expense) -51 305 -116.7%
Show Type Of Arrangement breakouts
Collaborative Arrangement -12 -11 -9.1%
Total Costs & Expenses 11,032 12,167 -9.3%
Income Before Taxes 1,470 175 +740.0%
Income Tax Expense (Benefit) 384 99 +287.9%
Net Income 1,085 76 +1327.6%
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest -1 4 -125.0%
Net Income 1,087 72 +1409.7%
EPS (Basic) 0.54 0.04 +1250.0%
EPS (Diluted) 0.53 0.04 +1225.0%
Interest Expense 432 496 -12.9%
Interest Income -148 -114 -29.8%
Comprehensive Income 1,075 302 +256.0%
Wtd Avg Shares (Basic) 0 1 -100.0%
Wtd Avg Shares (Diluted) 0 1 -100.0%
Income Loss From Equity Method Investments -100 -8 -1150.0%
Gain Loss On Investments -190 205 -192.7%

Balance Sheet

Balance Sheet
Metric Q4 2025 Q4 2024 YoY
Current Assets
Cash & Cash Equivalents 10,209 10,346 -1.3%
Available For Sale Securities Debt Securities Current 464 513 -9.6%
Receivables Net Current 11,414 10,747 +6.2%
Show Alliances and Collaboration Companies [Axis] breakouts
Pfizer · Collaborative Arrangement 176 189 -6.9%
Show Type Of Arrangement breakouts
Collaborative Arrangement 198 221 -10.4%
Inventory 2,690 2,557 +5.2%
Other Assets Current 4,613 5,617 -17.9%
Total Current Assets 29,390 29,780 -1.3%
Accounts Receivable 9,592 9,012 +6.4%
Non-Current Assets
Property, Plant & Equipment 7,543 7,136 +5.7%
Show Geography breakouts
Non Us 2,612 2,322 +12.5%
US 4,931 4,814 +2.4%
Goodwill 21,754 21,719 +0.2%
Deferred Tax Assets 5,378 4,236 +27.0%
Available For Sale Securities Debt Securities Noncurrent 396 320 +23.8%
Other Non-Current Assets 6,474 6,105 +6.0%
Total Assets 90,038 92,603 -2.8%
Operating Lease Right-of-Use Assets 1,582 1,224 +29.2%
Show Lease Contractual Term breakouts
Commencement of San Diego Lease 370 — —
Other Assets
Intangible Assets Net Excluding Goodwill 19,103 23,307 -18.0%
Show Finite Lived Intangible Assets By Major Class breakouts
Computer Software Intangible Asset 389 400 -2.8%
Licensing Agreements 1,375 1,705 -19.4%
Technology Based Intangible Assets 9,739 13,217 -26.3%
Show Indefinite Lived Intangible Assets By Major Class breakouts
In Process Research And Development 7,600 7,985 -4.8%
Current Liabilities
Debt Current 2,261 2,046 +10.5%
Accounts Payable 3,575 3,602 -0.7%
Show Alliances and Collaboration Companies [Axis] breakouts
Pfizer · Collaborative Arrangement 1,599 1,463 +9.3%
Show Type Of Arrangement breakouts
Collaborative Arrangement 1,684 1,578 +6.7%
Other Liabilities Current 17,581 18,126 -3.0%
Total Current Liabilities 23,417 23,774 -1.5%
Current Portion of Long-Term Debt 1,977 1,828 +8.2%
Non-Current Liabilities
Deferred Tax Liabilities 222 369 -39.8%
Long-Term Debt 42,850 47,603 -10.0%
Other Non-Current Liabilities 5,043 4,469 +12.8%
Total Liabilities 71,533 76,215 -6.1%
Long-Term Debt 44,827 49,431 -9.3%
Show Debt Instrument breakouts
3.200% To 6.875% For Notes Due 2026 To 2097 8,712 — —
Operating Lease Liabilities 1,826 1,370 +33.3%
Accrued Income Taxes Noncurrent 1,407 1,491 -5.6%
Stockholders' Equity
Common Stock Value Outstanding 292 292 0.0%
Additional Paid-In Capital 46,387 46,024 +0.8%
Accumulated Other Comprehensive Income -1,524 -1,238 -23.1%
Retained Earnings 16,896 14,912 +13.3%
Treasury Stock Common Value -43,579 -43,655 +0.2%
Total Stockholders' Equity 18,473 16,335 +13.1%
Minority Interest 33 53 -37.7%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 18,506 16,388 +12.9%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -1,524 -1,238 -23.1%
Additional Paid In Capital 46,387 46,024 +0.8%
Common Stock 292 292 0.0%
Noncontrolling Interest 33 53 -37.7%
Retained Earnings 16,896 14,912 +13.3%
Treasury Stock Common -43,579 -43,655 +0.2%
Total Liabilities & Equity 90,038 92,603 -2.8%
Preferred Stock Shares Outstanding 2,510 2,868 -12.5%
Preferred Stock Shares Issued 2,510 2,868 -12.5%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q4 2025 YTD Q4 2024 YoY
Operating Activities
Depreciation & Amortization 977 1,880 -48.0%
Deferred Income Taxes -392 -791 +50.4%
Stock-Based Compensation 133 120 +10.8%
Impairment Of Long Lived Assets To Be Disposed Of 584 1,953 -70.1%
Equity Method Investment Realized Gain Loss On Disposal -190 205 -192.7%
Other Non-Cash Items 308 -29 +1162.1%
Increase Decrease In Receivables 19 143 -86.7%
Change in Inventory 71 175 -59.4%
Change in Accounts Payable -90 517 -117.4%
Increase Decrease In Other Accrued Liabilities -2,398 -405 -492.1%
Increase Decrease In Accrued Income Taxes Payable -324 121 -367.8%
Increase Decrease In Other Operating Capital Net 1,068 725 +47.3%
Net Cash from Operations 1,974 4,439 -55.5%
Investing Activities
Proceeds From Sale And Maturity Of Available For Sale Securities 402 62 +548.4%
Payments To Acquire Marketable Securities -78 -371 +79.0%
Proceeds From Sale Of Equity Securities Fv Ni 16 205 -92.2%
Capital Expenditures -370 -378 +2.1%
Payments To Acquire Businesses Net Of Cash Acquired -1,707 -47 -3531.9%
Net Cash from Investing -1,458 -196 -643.9%
Financing Activities
Proceeds From Other Short Term Debt -406 -405 -0.2%
Repayments Of Long Term Debt -10,068 0 —
Payments Of Dividends -1,262 -1,218 -3.6%
Payments For Proceeds From Stock Option Exercises And Other Adjustments -33 -19 -73.7%
Net Cash from Financing -6,029 -1,642 -267.2%
Supplemental
Income Taxes Paid 3,261.8 0.8 +407625.0%
Interest Paid 0.4 0.4 0.0%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 5 -147 +103.4%
Net Change in Cash -5,508 2,454 -324.4%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 10,218 10,347 -1.2%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key